Moreover, suppression of MTBP expression in malignant cells or expression of a mutant with apparent dominant-negative activity demonstrated MTBP-directed therapeutics could have broad applicability as cancer therapies and extending patient survival [3,4,8,11], similar to its binding partner MYC. The gene discussed is MTBP; the disease is cancer.